摘要
目的系统评价消癌平注射液联合化学治疗（化疗）对非小细胞肺癌的临床疗效及安全性。方法采用Meta分析方法，制定原始文献的纳入标准、排除标准及检索策略，计算机检索中国知网（1979年～2012年）、维普数据库（1989年～2012年）和万方数字化期刊群（1998年～2011年）和Pubmed数据库，按Cochrane评价标准评价文献质量。结果共纳入11个研究。消癌平注射液联合化疗治疗非小细胞肺癌的合并有效率为50．41％（95％CI：45．12％～55．70％），单用化疗的合并有效率为39．44％（95％CI：34．33％～44．62％）。消癌平注射液联合化疗的有效率是单用化疗的1．28倍，差异有统计学意义（95％CI：1．09～1．52，P〈0．01）；生活质量提高率是单用化疗的1．90倍（95％CI：1．55～2．33，P〈0．01）；白细胞减少发生率比单用化疗降低25％，差异有统计学意义（RR=0．75，95％CI：0．59～0．96，P〈0．05），其他不良反应两组差异无统计学意义。结论消癌平注射液联合化疗治疗非小细胞肺癌的有效率、生活质量提高率均优于单用化疗，白细胞减少发生率低于单用化疗。
Objective To evaluate the clinical efficacy and safety of xiaoaiping injection combined with chemotherapy on patients with non-small cell lung cancer（NSCLC）. Methods The inclusion and exclusion criteria and retrieval strategies of original documents, computer retrieval of CNKI （ 1979-2012）, WEP database （1989-2012） and the journal of digital periodicals （1998- 2011 ） and Pubmed database with computer were developed by using Meta analysis methods, and the quality of literatures was assessed according to Cochrane review criteria. Results Eleven researches were included. It was shown that the efficacy of xiaoaiping injection combined with chemotherapy was 50.41% （95% C1：45.12% -55. 70% ）, 1.28 times（95% CI： 1.09-1.52,P〈0.01 ） of chemotherapy alone （ 39.44%, 95% CI： 34.33% -44.62% ）. Xiaoaiping injection combined with chemotherapy improved quality of life 1.90 times as much as chemotherapy alone （95% CI：I. 55-2.33 ,P〈0.01 ）, and lowered the incidence of leukocyte reduction by 25% in comparison to chemotherapy alone（ RR = 0.75, 95% C1：0. 59-0. 96, P〈0.05 ）. No significant difference in occurrence of adverse reactions was observed between the two treatments. Conclusion The combination of xiaoaiping injection with chemotherapy can improve the efficacy and quality of life, reduce the incidence of leukocyte reduction compared with using chemotherapy alone for patients with NSCLC.
出处
《医药导报》
CAS
北大核心
2014年第1期48-53,共6页
Herald of Medicine
